↓ Skip to main content

The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011

Overview of attention for article published in Einstein (São Paulo), June 2015
Altmetric Badge

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011
Published in
Einstein (São Paulo), June 2015
DOI 10.1590/s1679-45082015ao3326
Pubmed ID
Authors

Cinthia Leite Frizzera Borges Bognar, Sergio Daniel Simon, Rene Claudio Gansl, Roberto Abramoff, Marcelo Aisen, Gilberto de Lima Lopes Junior, Oren Smaletz, Stela Verzinhasse Peres, Jacques Tabacof

Abstract

To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature. A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference. We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 30%
Researcher 5 25%
Student > Master 5 25%
Student > Ph. D. Student 1 5%
Student > Doctoral Student 1 5%
Other 1 5%
Unknown 1 5%
Readers by discipline Count As %
Medicine and Dentistry 10 50%
Psychology 2 10%
Nursing and Health Professions 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Agricultural and Biological Sciences 1 5%
Other 3 15%
Unknown 2 10%